Our results demonstrate that the HDAC6-selective inhibitors ACY-1215 and ACY-241 alter melanoma patient T-cell phenotypes and function ex vivo at concentrations achievable in human patients [41], resulting in enhanced effector function without impacting viability. This evidence concerns the gene HDAC6 and melanoma.